Landmark Bio https://validator.w3.org/feed/docs/rss2.html Home Artis BioSolutions Establishes U.S.-based Synthetic DNA Manufacturing Hub in Boston Landmark Bio Secures Up to $18.3 Million ARPA-H Award to Build a Scalable Continuous Manufacturing Platform for Extracellular Vesicle Therapies Artis BioSolutions Announces Agreement to Acquire Syngoi Technologies to Deliver Next Generation Solutions for Synthetic DNA Technology Flexible Partnership Models About Leeza Frantz Peter Stolba Mike Houston, Ph.D. Brian Neel Contact Kris Ward Gregg Nyberg Landmark Bio Forges New Collaboration to Accelerate Early-Stage Translational Cell and Gene Therapies Amanda Owens Eli Kraus Integrating AI & ML in Biotech Manufacturing: How Modern Technology is Revolutionizing the Production of Advanced Therapies Landmark Bio’s Mission to Prevent Cell Therapy ‘Do-overs’ Integrating Analytical Method Development and Quality Control ChromaTan and Landmark Bio Awarded National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) Grant to Advance Intensified Recombinant Adeno-Associated Virus (AAV) Production Process From Research to Reality: Overcoming CMC Challenges in Cell & Gene Therapy Landmark Bio Acquired by Artis BioSolutions to Expand Manufacturing and Commercialization of Advanced Therapies Michael Sousa Olga Mollin Know Your Product, Know Your Path: Cell & Gene Therapy Manufacturing Getting Tech Transfer Right First Time Use of Conventional Flow Cytometry to Study Extracellular Vesicles Optimization of In Vitro Transcription for mRNA Production Formulation Matters Nucleic Acids Landmark Bio Unveils New State-of-the-Art Full-Spectrum Biomanufacturing Innovation Center Landmark Bio Partners With InnDura Therapeutics to Advance Immune Cell Therapy Research Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos’ Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care The Harvard Gazette: Veteran biotech executive to run new center aimed at boosting cell and gene therapies Harvard Magazine: Landmark Bio Breaks Ground Science Technology Careers Landmark Bio Appoints Gregg Nyberg, Ph.D., as Chief Technology Officer and Michael Covington as Chief Quality and Regulatory Officer Introducing Landmark Bio and Appointment of Ran Zheng as CEO Publications News Technology Development IND-Enabling Services CMC Regulatory & Drug Development Consulting Quality Control Testing Fill & Finish Formulation Development Process & Analytical Development Nanoparticles & Non-viral Delivery